106 related articles for article (PubMed ID: 25580906)
41. An insight on medicinal attributes of 1,2,4-triazoles.
Aggarwal R; Sumran G
Eur J Med Chem; 2020 Nov; 205():112652. PubMed ID: 32771798
[TBL] [Abstract][Full Text] [Related]
42. Planning new Trypanosoma cruzi CYP51 inhibitors using QSAR studies.
de Oliveira PIC; de Santana Miranda PH; Lourenço EMG; de Santana Nogueira Silverio PS; Barbosa EG
Mol Divers; 2021 Nov; 25(4):2219-2235. PubMed ID: 32557280
[TBL] [Abstract][Full Text] [Related]
43. Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
An Y; Dong Y; Min L; Zhao L; Zhao D; Han J; Sun B
ACS Med Chem Lett; 2020 Jun; 11(6):1152-1159. PubMed ID: 32550995
[TBL] [Abstract][Full Text] [Related]
44. Fluconazole analogues with metal-binding motifs impact metal-dependent processes and demonstrate antifungal activity in Candida albicans.
Hunsaker EW; McAuliffe KJ; Franz KJ
J Biol Inorg Chem; 2020 Aug; 25(5):729-745. PubMed ID: 32542530
[TBL] [Abstract][Full Text] [Related]
45. Current trends in the pharmacological management of Chagas disease.
Ribeiro V; Dias N; Paiva T; Hagström-Bex L; Nitz N; Pratesi R; Hecht M
Int J Parasitol Drugs Drug Resist; 2020 Apr; 12():7-17. PubMed ID: 31862616
[TBL] [Abstract][Full Text] [Related]
46. Chagas Disease Treatment and Rational Drug Discovery: A Challenge That Remains.
Silva ACC; Brelaz-de-Castro MCA; Leite ACL; Pereira VRA; Hernandes MZ
Front Pharmacol; 2019; 10():873. PubMed ID: 31427977
[No Abstract] [Full Text] [Related]
47. Quantitative Structure-Activity Relationships for Structurally Diverse Chemotypes Having Anti-
de Souza AS; Ferreira LLG; de Oliveira AS; Andricopulo AD
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181717
[TBL] [Abstract][Full Text] [Related]
48. Combined Strategies to Improve the Expression of Recombinant Sterol C24-Methyltransferase from Leishmania braziliensis in E. coli.
Freitas HF; Pires ABL; Castilho MS
Mol Biotechnol; 2018 Apr; 60(4):271-278. PubMed ID: 29488127
[TBL] [Abstract][Full Text] [Related]
49. Nitrotriazole-Based Compounds as Antichagasic Agents in a Long-Treatment
Papadopoulou MV; Bloomer WD; Rosenzweig HS; Mazzeti AL; Gonçalves KR; Mendes PF; Bahia MT
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242662
[TBL] [Abstract][Full Text] [Related]
50. Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.
Papadopoulou MV; Bloomer WD; Rosenzweig HS; Wilkinson SR; Szular J; Kaiser M
Eur J Med Chem; 2016 Nov; 123():895-904. PubMed ID: 27543881
[TBL] [Abstract][Full Text] [Related]
51. Quinolone Amides as Antitrypanosomal Lead Compounds with In Vivo Activity.
Hiltensperger G; Hecht N; Kaiser M; Rybak JC; Hoerst A; Dannenbauer N; Müller-Buschbaum K; Bruhn H; Esch H; Lehmann L; Meinel L; Holzgrabe U
Antimicrob Agents Chemother; 2016 Aug; 60(8):4442-52. PubMed ID: 27139467
[TBL] [Abstract][Full Text] [Related]
52. Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.
Papadopoulou MV; Bloomer WD; Rosenzweig HS; Wilkinson SR; Szular J; Kaiser M
Eur J Med Chem; 2016 Jul; 117():179-86. PubMed ID: 27092415
[TBL] [Abstract][Full Text] [Related]
53. Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.
Hoekstra WJ; Hargrove TY; Wawrzak Z; da Gama Jaen Batista D; da Silva CF; Nefertiti AS; Rachakonda G; Schotzinger RJ; Villalta F; Soeiro Mde N; Lepesheva GI
Antimicrob Agents Chemother; 2016 Feb; 60(2):1058-66. PubMed ID: 26643331
[TBL] [Abstract][Full Text] [Related]
54. Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
Papadopoulou MV; Bloomer WD; Rosenzweig HS; O'Shea IP; Wilkinson SR; Kaiser M; Chatelain E; Ioset JR
Bioorg Med Chem; 2015 Oct; 23(19):6467-76. PubMed ID: 26344593
[TBL] [Abstract][Full Text] [Related]
55. 3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
Papadopoulou MV; Bloomer WD; Rosenzweig HS; O'Shea IP; Wilkinson SR; Kaiser M
Eur J Med Chem; 2015 Oct; 103():325-34. PubMed ID: 26363868
[TBL] [Abstract][Full Text] [Related]
56. Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
Papadopoulou MV; Bloomer WD; Rosenzweig HS; Wilkinson SR; Kaiser M
Eur J Med Chem; 2014 Nov; 87():79-88. PubMed ID: 25240098
[TBL] [Abstract][Full Text] [Related]
57. Examination of multiple Trypanosoma cruzi targets in a new drug discovery approach for Chagas disease.
Beltran-Hortelano I; Alcolea V; Font M; Pérez-Silanes S
Bioorg Med Chem; 2022 Mar; 58():116577. PubMed ID: 35189560
[TBL] [Abstract][Full Text] [Related]
58. Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51).
Lepesheva GI; Villalta F; Waterman MR
Adv Parasitol; 2011; 75():65-87. PubMed ID: 21820552
[TBL] [Abstract][Full Text] [Related]
59. Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
Papadopoulou MV; Bloomer WD; Lepesheva GI; Rosenzweig HS; Kaiser M; Aguilera-Venegas B; Wilkinson SR; Chatelain E; Ioset JR
J Med Chem; 2015 Feb; 58(3):1307-19. PubMed ID: 25580906
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
